Palomino-Antolín Alejandra, Decouty-Pérez Céline, Farré-Alins Víctor, Narros-Fernández Paloma, Lopez-Rodriguez Ana Belen, Álvarez-Rubal María, Valencia Inés, López-Muñoz Francisco, Ramos Eva, Cuadrado Antonio, Casas Ana I, Romero Alejandro, Egea Javier
Unidad de Investigación, Hospital Santa Cristina, Instituto de Investigación Sanitaria Princesa (IIS-IP), 28006 Madrid, Spain.
Faculty of Health, Camilo José Cela University of Madrid (UCJC), 28692 Madrid, Spain.
Antioxidants (Basel). 2023 Sep 7;12(9):1729. doi: 10.3390/antiox12091729.
The role of inflammation and immunity in the pathomechanism of neurodegenerative diseases has become increasingly relevant within the past few years. In this context, the NOD-like receptor protein 3 (NLRP3) inflammasome plays a crucial role in the activation of inflammatory responses by promoting the maturation and secretion of pro-inflammatory cytokines such as interleukin-1β and interleukin-18. We hypothesized that the interplay between nuclear factor erythroid 2-related factor 2 (Nrf2) and NADPH oxidase 4 (NOX4) may play a critical role in the activation of the NLRP3 inflammasome and subsequent inflammatory responses. After priming mixed glial cultures with lipopolysaccharide (LPS), cells were stimulated with ATP, showing a significant reduction of IL1-β release in NOX4 and Nrf2 KO mice. Importantly, NOX4 inhibition using GKT136901 also reduced IL-1β release, as in NOX4 KO mixed glial cultures. Moreover, we measured NOX4 and NLRP3 expression in wild-type mixed glial cultures following LPS treatment, observing that both increased after TLR4 activation, while 24 h treatment with tert-butylhydroquinone, a potent Nrf2 inducer, significantly reduced NLRP3 expression. LPS administration resulted in significant cognitive impairment compared to the control group. Indeed, LPS also modified the expression of NLRP3 and NOX4 in mouse hippocampus. However, mice treated with GKT136901 after LPS impairment showed a significantly improved discrimination index and recovered the expression of inflammatory genes to normal levels compared with wild-type animals. Hence, we here validate NOX4 as a key player in NLRP3 inflammasome activation, suggesting NOX4 pharmacological inhibition as a potent therapeutic approach in neurodegenerative diseases.
在过去几年中,炎症和免疫在神经退行性疾病发病机制中的作用愈发重要。在此背景下,NOD样受体蛋白3(NLRP3)炎性小体通过促进促炎细胞因子如白细胞介素-1β和白细胞介素-18的成熟和分泌,在炎症反应激活中起关键作用。我们推测核因子红细胞2相关因子2(Nrf2)和NADPH氧化酶4(NOX4)之间的相互作用可能在NLRP3炎性小体激活及随后的炎症反应中起关键作用。在用脂多糖(LPS)预处理混合胶质细胞培养物后,用ATP刺激细胞,结果显示在NOX4和Nrf2基因敲除小鼠中白细胞介素-1β释放显著减少。重要的是,与NOX4基因敲除的混合胶质细胞培养物一样,使用GKT136901抑制NOX4也能减少白细胞介素-1β的释放。此外,我们检测了LPS处理后野生型混合胶质细胞培养物中NOX4和NLRP3的表达,发现TLR4激活后两者均增加,而用强效Nrf2诱导剂叔丁基对苯二酚处理24小时后,NLRP3表达显著降低。与对照组相比,给予LPS导致显著的认知障碍。事实上,LPS还改变了小鼠海马体中NLRP3和NOX4的表达。然而,在LPS损伤后用GKT136901处理的小鼠与野生型动物相比,辨别指数显著改善,炎症基因表达恢复到正常水平。因此,我们在此证实NOX4是NLRP3炎性小体激活的关键因素,提示对NOX4进行药理学抑制是神经退行性疾病的一种有效治疗方法。